{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T02:47:12Z","timestamp":1782182832422,"version":"3.54.5"},"reference-count":63,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,3]],"date-time":"2026-05-03T00:00:00Z","timestamp":1777766400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T00:00:00Z","timestamp":1782172800000},"content-version":"vor","delay-in-days":51,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["acta neuropathol commun"],"DOI":"10.1186\/s40478-026-02310-1","type":"journal-article","created":{"date-parts":[[2026,5,3]],"date-time":"2026-05-03T03:44:17Z","timestamp":1777779857000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Immune landscape characterization of neurofibromas with atypical features in Neurofibromatosis1 reveals PD-1 and the Tim-3\/Galectin-9 pathway as potential therapeutic targets"],"prefix":"10.1186","volume":"14","author":[{"given":"Ana\u00efs","family":"Brunet","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fanny","family":"Coulpier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Audrey","family":"Onfroy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nouhoum","family":"Sako","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katarzyna J.","family":"Radomska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Val\u00e9rie","family":"Aftimos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laetitia","family":"Lacroix","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Audrey","family":"Briand-Suleau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pascale","family":"Maille","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oana","family":"Hermeziu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ingrid","family":"Laurendeau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Pasmant","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre","family":"Wolkenstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Piotr","family":"Topilko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolas","family":"Ortonne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,3]]},"reference":[{"key":"2310_CR1","unstructured":"Friedman JM (1993) Neurofibromatosis 1. In: Adam MP, Ardinger HH, Pagon RA, Wallace SE, Bean LJ, Stephens K et al. (eds) GeneReviews\u00ae [Internet]. Seattle (WA): University of Washington, Seattle"},{"key":"2310_CR2","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1038\/nrc3911","volume":"15","author":"N Ratner","year":"2015","unstructured":"Ratner N, Miller SJ (2015) A RASopathy gene commonly mutated in cancer: the neurofibromatosis type 1 tumour suppressor. Nat Rev Cancer 15:290\u2013301","journal-title":"Nat Rev Cancer"},{"key":"2310_CR3","doi-asserted-by":"publisher","first-page":"3168","DOI":"10.1038\/onc.2016.464","volume":"36","author":"A Pemov","year":"2017","unstructured":"Pemov A, Li H, Patidar R, Hansen NF, Sindiri S, Hartley SW et al (2017) The primacy of NF1 loss as the driver of tumorigenesis in neurofibromatosis type 1-associated plexiform neurofibromas. Oncogene 36:3168\u20133177","journal-title":"Oncogene"},{"key":"2310_CR4","doi-asserted-by":"publisher","first-page":"1643","DOI":"10.1093\/neuonc\/noy067","volume":"20","author":"AM Gross","year":"2018","unstructured":"Gross AM, Singh G, Akshintala S, Baldwin A, Dombi E, Ukwuani S et al (2018) Association of plexiform neurofibroma volume changes and development of clinical morbidities in neurofibromatosis 1. Neuro Oncol 20:1643\u20131651","journal-title":"Neuro Oncol"},{"key":"2310_CR5","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1002\/(SICI)1096-8628(19990326)89:1<31::AID-AJMG7>3.0.CO;2-W","volume":"89","author":"BR Korf","year":"1999","unstructured":"Korf BR (1999) Plexiform neurofibromas. Am J Med Genet 89:31\u201337","journal-title":"Am J Med Genet"},{"key":"2310_CR6","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1212\/01.wnl.0000168830.79997.13","volume":"65","author":"T Tucker","year":"2005","unstructured":"Tucker T, Wolkenstein P, Revuz J, Zeller J, Friedman JM (2005) Association between benign and malignant peripheral nerve sheath tumors in NF1. Neurology 65:205\u2013211","journal-title":"Neurology"},{"key":"2310_CR7","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1136\/jmg.39.5.311","volume":"39","author":"DGR Evans","year":"2002","unstructured":"Evans DGR, Baser ME, McGaughran J, Sharif S, Howard E, Moran A (2002) Malignant peripheral nerve sheath tumours in neurofibromatosis 1. J Med Genet 39:311\u2013314","journal-title":"J Med Genet"},{"key":"2310_CR8","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.ejca.2015.12.015","volume":"56","author":"T Valentin","year":"2016","unstructured":"Valentin T, Le Cesne A, Ray-Coquard I, Italiano A, Decanter G, Bompas E et al (2016) Management and prognosis of malignant peripheral nerve sheath tumors: the experience of the French Sarcoma Group (GSF-GETO). Eur J Cancer 56:77\u201384","journal-title":"Eur J Cancer"},{"key":"2310_CR9","doi-asserted-by":"publisher","first-page":"1008","DOI":"10.1111\/j.1365-2133.2008.08494.x","volume":"158","author":"L Valeyrie-Allanore","year":"2008","unstructured":"Valeyrie-Allanore L, Ortonne N, Lantieri L, Ferkal S, Wechsler J, Bagot M et al (2008) Histopathologically dysplastic neurofibromas in neurofibromatosis 1: diagnostic criteria, prevalence and clinical significance. Br J Dermatol 158:1008\u20131012","journal-title":"Br J Dermatol"},{"key":"2310_CR10","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.humpath.2017.05.010","volume":"67","author":"MM Miettinen","year":"2017","unstructured":"Miettinen MM, Antonescu CR, Fletcher CDM, Kim A, Lazar AJ, Quezado MM et al (2017) Histopathologic evaluation of atypical neurofibromatous tumors and their transformation into malignant peripheral nerve sheath tumor in patients with neurofibromatosis 1-a consensus overview. Hum Pathol 67:1\u201310","journal-title":"Hum Pathol"},{"key":"2310_CR11","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1093\/neuonc\/noae235","volume":"27","author":"C-HG Lucas","year":"2025","unstructured":"Lucas C-HG, Gross AM, Romo CG, Dehner CA, Lazar AJ, Miettinen M et al (2025) Consensus recommendations for an integrated diagnostic approach to peripheral nerve sheath tumors arising in the setting of Neurofibromatosis Type 1. Neuro Oncol 27:616\u2013624","journal-title":"Neuro Oncol"},{"key":"2310_CR12","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1002\/jso.23736","volume":"110","author":"NM Bernthal","year":"2014","unstructured":"Bernthal NM, Putnam A, Jones KB, Viskochil D, Randall RL (2014) The effect of surgical margins on outcomes for low grade MPNSTs and atypical neurofibroma. J Surg Oncol 110:813\u2013816","journal-title":"J Surg Oncol"},{"key":"2310_CR13","doi-asserted-by":"publisher","first-page":"818","DOI":"10.1093\/neuonc\/noy013","volume":"20","author":"CS Higham","year":"2018","unstructured":"Higham CS, Dombi E, Rogiers A, Bhaumik S, Pans S, Connor SEJ et al (2018) The characteristics of 76 atypical neurofibromas as precursors to neurofibromatosis 1 associated malignant peripheral nerve sheath tumors. Neuro Oncol 20:818\u2013825","journal-title":"Neuro Oncol"},{"key":"2310_CR14","doi-asserted-by":"publisher","first-page":"1112","DOI":"10.1002\/humu.23552","volume":"39","author":"M Carri\u00f3","year":"2018","unstructured":"Carri\u00f3 M, Gel B, Terribas E, Zucchiatti AC, Molin\u00e9 T, Rosas I et al (2018) Analysis of intratumor heterogeneity in Neurofibromatosis type 1 plexiform neurofibromas and neurofibromas with atypical features: Correlating histological and genomic findings. Hum Mutat 39:1112\u20131125","journal-title":"Hum Mutat"},{"key":"2310_CR15","doi-asserted-by":"publisher","first-page":"1241","DOI":"10.1007\/s00439-021-02296-x","volume":"140","author":"M Magall\u00f3n-Lorenz","year":"2021","unstructured":"Magall\u00f3n-Lorenz M, Fern\u00e1ndez-Rodr\u00edguez J, Terribas E, Creus-Batchiller E, Romagosa C, Estival A et al (2021) Chromosomal translocations inactivating CDKN2A support a single path for malignant peripheral nerve sheath tumor initiation. Hum Genet 140:1241\u20131252","journal-title":"Hum Genet"},{"issue":"8","key":"2310_CR16","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1093\/neuonc\/noz028","volume":"21","author":"A Pemov","year":"2019","unstructured":"Pemov A, Hansen NF, Sindiri S, Patidar R, Higham CS, Dombi E et al (2019) Low mutation burden and frequent loss of CDKN2A\/B and SMARCA2, but not PRC2, define pre-malignant neurofibromatosis type 1-associated atypical neurofibromas. Neuro Oncol 21(8):981\u2013992","journal-title":"Neuro Oncol"},{"key":"2310_CR17","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1038\/nature13561","volume":"514","author":"T De Raedt","year":"2014","unstructured":"De Raedt T, Beert E, Pasmant E, Luscan A, Brems H, Ortonne N et al (2014) PRC2 loss amplifies Ras-driven transcription and confers sensitivity to BRD4-based therapies. Nature 514:247\u2013251","journal-title":"Nature"},{"key":"2310_CR18","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1002\/gcc.22446","volume":"56","author":"P Sohier","year":"2017","unstructured":"Sohier P, Luscan A, Lloyd A, Ashelford K, Laurendeau I, Briand-Suleau A et al (2017) Confirmation of mutation landscape of NF1-associated malignant peripheral nerve sheath tumors. Genes Chromosom Cancer 56:421\u2013426","journal-title":"Genes Chromosom Cancer"},{"key":"2310_CR19","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-38432-6","volume":"14","author":"S Suppiah","year":"2023","unstructured":"Suppiah S, Mansouri S, Mamatjan Y, Liu JC, Bhunia MM, Patil V et al (2023) Multiplatform molecular profiling uncovers two subgroups of malignant peripheral nerve sheath tumors with distinct therapeutic vulnerabilities. Nat Commun 14:2696","journal-title":"Nat Commun"},{"key":"2310_CR20","doi-asserted-by":"publisher","first-page":"82037","DOI":"10.18632\/oncotarget.18301","volume":"8","author":"KB Haworth","year":"2017","unstructured":"Haworth KB, Arnold MA, Pierson CR, Choi K, Yeager ND, Ratner N et al (2017) Immune profiling of NF1-associated tumors reveals histologic subtype distinctions and heterogeneity: implications for immunotherapy. Oncotarget 8:82037\u201382048","journal-title":"Oncotarget"},{"key":"2310_CR21","doi-asserted-by":"publisher","first-page":"64300","DOI":"10.18632\/oncotarget.11734","volume":"7","author":"E Shurell","year":"2016","unstructured":"Shurell E, Singh AS, Crompton JG, Jensen S, Li Y, Dry S et al (2016) Characterizing the immune microenvironment of malignant peripheral nerve sheath tumor by PD-L1 expression and presence of CD8+ tumor infiltrating lymphocytes. Oncotarget 7:64300\u201364308","journal-title":"Oncotarget"},{"key":"2310_CR22","doi-asserted-by":"publisher","first-page":"5781","DOI":"10.1038\/s41388-021-01979-z","volume":"40","author":"C Jiang","year":"2021","unstructured":"Jiang C, McKay RM, Le LQ (2021) Tumorigenesis in neurofibromatosis type 1: role of the microenvironment. Oncogene 40:5781\u20135787","journal-title":"Oncogene"},{"key":"2310_CR23","doi-asserted-by":"publisher","first-page":"45","DOI":"10.2217\/cns-2016-0024","volume":"6","author":"S Karmakar","year":"2017","unstructured":"Karmakar S, Reilly KM (2017) The role of the immune system in Neurofibromatosis type 1-associated nervous system tumors. CNS Oncol 6:45\u201360","journal-title":"CNS Oncol"},{"key":"2310_CR24","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1016\/j.cell.2008.08.041","volume":"135","author":"F-C Yang","year":"2008","unstructured":"Yang F-C, Ingram DA, Chen S, Zhu Y, Yuan J, Li X et al (2008) Nf1-dependent tumors require a microenvironment containing Nf1+\/\u2013 and c-kit-dependent bone marrow. Cell 135:437\u2013448","journal-title":"Cell"},{"key":"2310_CR25","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1007\/s00401-012-1056-7","volume":"125","author":"CE Prada","year":"2013","unstructured":"Prada CE, Jousma E, Rizvi TA, Wu J, Dunn RS, Mayes DA et al (2013) Neurofibroma-associated macrophages play roles in tumor growth and response to pharmacological inhibition. Acta Neuropathol 125:159\u2013168","journal-title":"Acta Neuropathol"},{"key":"2310_CR26","doi-asserted-by":"publisher","first-page":"5459","DOI":"10.1158\/1078-0432.CCR-24-1454","volume":"30","author":"L Zhang","year":"2024","unstructured":"Zhang L, Maalouf A, Makri SC, Banerjee J, Suru A, Tam AJ et al (2024) Multidimensional immunotyping of human NF1-associated peripheral nerve sheath tumors uncovers tumor-associated macrophages as key drivers of immune evasion in the tumor microenvironment. Clin Cancer Res 30:5459\u20135472","journal-title":"Clin Cancer Res"},{"key":"2310_CR27","doi-asserted-by":"publisher","first-page":"1506","DOI":"10.1038\/s41436-021-01170-5","volume":"23","author":"E Legius","year":"2021","unstructured":"Legius E, Messiaen L, Wolkenstein P, Pancza P, Avery RA, Berman Y et al (2021) Revised diagnostic criteria for neurofibromatosis type 1 and Legius syndrome: an international consensus recommendation. Genet Med 23:1506\u20131513","journal-title":"Genet Med"},{"key":"2310_CR28","unstructured":"WHO Classification of Tumours (2020) Soft tissue and bone tumours. 5th ed. Lyon, France: International agency for research on cancer"},{"key":"2310_CR29","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1038\/ejhg.2014.145","volume":"23","author":"E Pasmant","year":"2015","unstructured":"Pasmant E, Parfait B, Luscan A, Goussard P, Briand-Suleau A, Laurendeau I et al (2015) Neurofibromatosis type 1 molecular diagnosis: what can NGS do for you when you have a large gene with loss of function mutations? Eur J Hum Genet 23:596\u2013601","journal-title":"Eur J Hum Genet"},{"issue":"46","key":"2310_CR30","doi-asserted-by":"publisher","first-page":"eadt9210","DOI":"10.1126\/sciadv.adt9210","volume":"11","author":"KJ Radomska","year":"2025","unstructured":"Radomska KJ, Onfroy A, Lecerf L, Job B, Beaude A, Sesma Sanz L et al (2025) Glial-to-mesenchymal transition of tumor Schwann cells drives the genetic burden in MPNSTs from Neurofibromatosis type 1 mouse model. Sci Adv 11(46):eadt9210","journal-title":"Sci Adv"},{"key":"2310_CR31","doi-asserted-by":"publisher","first-page":"1397","DOI":"10.1016\/j.stem.2021.04.029","volume":"28","author":"D Sun","year":"2021","unstructured":"Sun D, Xie XP, Zhang X, Wang Z, Sait SF, Iyer SV et al (2021) Stem-like cells drive NF1-associated MPNST functional heterogeneity and tumor progression. Cell Stem Cell 28:1397-1410.e4","journal-title":"Cell Stem Cell"},{"key":"2310_CR32","doi-asserted-by":"publisher","first-page":"eabo5442","DOI":"10.1126\/sciadv.abo5442","volume":"8","author":"LMN Wu","year":"2022","unstructured":"Wu LMN, Zhang F, Rao R, Adam M, Pollard K, Szabo S et al (2022) Single-cell multiomics identifies clinically relevant mesenchymal stem-like cells and key regulators for MPNST malignancy. Sci Adv 8:eabo5442","journal-title":"Sci Adv"},{"key":"2310_CR33","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1158\/2159-8290.CD-18-0156","volume":"9","author":"KJ Radomska","year":"2019","unstructured":"Radomska KJ, Coulpier F, Gresset A, Schmitt A, Debbiche A, Lemoine S et al (2019) Cellular origin, tumor progression, and pathogenic mechanisms of cutaneous neurofibromas revealed by mice with Nf1 knockout in boundary cap cells. Cancer Discov 9:130\u2013147","journal-title":"Cancer Discov"},{"key":"2310_CR34","doi-asserted-by":"publisher","first-page":"1344","DOI":"10.1037\/hea0000094","volume":"33","author":"ME Slovinec D\u2019Angelo","year":"2014","unstructured":"Slovinec D\u2019Angelo ME, Pelletier LG, Reid RD, Huta V (2014) The roles of self-efficacy and motivation in the prediction of short- and long-term adherence to exercise among patients with coronary heart disease. Health Psychol 33:1344\u20131353","journal-title":"Health Psychol"},{"key":"2310_CR35","doi-asserted-by":"publisher","first-page":"1493","DOI":"10.1016\/S1470-2045(17)30624-1","volume":"18","author":"HA Tawbi","year":"2017","unstructured":"Tawbi HA, Burgess M, Bolejack V, Van Tine BA, Schuetze SM, Hu J et al (2017) Pembrolizumab in advanced soft-tissue sarcoma and bone sarcoma (SARC028): a multicentre, two-cohort, single-arm, open-label, phase 2 trial. Lancet Oncol 18:1493\u20131501","journal-title":"Lancet Oncol"},{"key":"2310_CR36","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1001\/jamaoncol.2017.1617","volume":"4","author":"M Toulmonde","year":"2018","unstructured":"Toulmonde M, Penel N, Adam J, Chevreau C, Blay J-Y, Le Cesne A et al (2018) Use of PD-1 targeting, macrophage infiltration, and IDO pathway activation in sarcomas: a phase 2 clinical trial. JAMA Oncol 4:93\u201397","journal-title":"JAMA Oncol"},{"key":"2310_CR37","first-page":"182","volume":"7","author":"M Payandeh","year":"2017","unstructured":"Payandeh M, Sadeghi M, Sadeghi E (2017) Complete response to Pembrolizumab in a patient with malignant peripheral nerve sheath tumor: the first case reported. J App Pharm Sci 7:182\u2013184","journal-title":"J App Pharm Sci"},{"key":"2310_CR38","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1200\/PO.18.00375","volume":"3","author":"BC \u00d6zdemir","year":"2019","unstructured":"\u00d6zdemir BC, Bohanes P, Bisig B, Missiaglia E, Tsantoulis P, Coukos G et al (2019) Deep Response to Anti-PD-1 therapy of metastatic neurofibromatosis type 1-associated malignant peripheral nerve sheath tumor with CD274\/PD-L1 amplification. JCO Precis Oncol 3:1\u20136","journal-title":"JCO Precis Oncol"},{"key":"2310_CR39","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1097\/CJI.0000000000000410","volume":"45","author":"K Larson","year":"2022","unstructured":"Larson K, Russ A, Arif-Tiwari H, Mahadevan D, Elliott A, Bhattacharyya A et al (2022) Pembrolizumab achieves a complete response in an NF-1 mutated, PD-L1 positive malignant peripheral nerve sheath tumor: a case report and review of the benchmarks. J Immunother 45:222\u2013226","journal-title":"J Immunother"},{"key":"2310_CR40","doi-asserted-by":"publisher","first-page":"1396","DOI":"10.1158\/2326-6066.CIR-19-0072","volume":"7","author":"LE Davis","year":"2019","unstructured":"Davis LE, Nicholls LA, Babiker HM, Liau J, Mahadevan D (2019) PD-1 inhibition achieves a complete metabolic response in a patient with malignant peripheral nerve sheath tumor. Cancer Immunol Res 7:1396\u20131400","journal-title":"Cancer Immunol Res"},{"key":"2310_CR41","doi-asserted-by":"publisher","DOI":"10.1016\/j.jid.2024.01.028","author":"L Fertitta","year":"2024","unstructured":"Fertitta L, Jannic A, Zehou O, Bergqvist C, Ferkal S, Moryousef M et al (2024) Whole-body positron emission tomography with (18)F-Fluorodeoxyglucose\/Magnetic Resonance Imaging as a screening tool for the detection of malignant transformation in individuals with Neurofibromatosis Type 1. J Invest Dermatol. https:\/\/doi.org\/10.1016\/j.jid.2024.01.028.","journal-title":"J Invest Dermatol"},{"key":"2310_CR42","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1016\/j.imlet.2019.11.005","volume":"217","author":"E Sparrow","year":"2020","unstructured":"Sparrow E, Bodman-Smith MD (2020) Granulysin: the attractive side of a natural born killer. Immunol Lett 217:126\u2013132","journal-title":"Immunol Lett"},{"key":"2310_CR43","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1007\/s00401-016-1540-6","volume":"131","author":"M R\u00f6hrich","year":"2016","unstructured":"R\u00f6hrich M, Koelsche C, Schrimpf D, Capper D, Sahm F, Kratz A et al (2016) Methylation-based classification of benign and malignant peripheral nerve sheath tumors. Acta Neuropathol 131:877\u2013887","journal-title":"Acta Neuropathol"},{"key":"2310_CR44","doi-asserted-by":"publisher","first-page":"43315","DOI":"10.1038\/srep43315","volume":"7","author":"K Choi","year":"2017","unstructured":"Choi K, Komurov K, Fletcher JS, Jousma E, Cancelas JA, Wu J et al (2017) An inflammatory gene signature distinguishes neurofibroma Schwann cells and macrophages from cells in the normal peripheral nervous system. Sci Rep 7:43315","journal-title":"Sci Rep"},{"key":"2310_CR45","doi-asserted-by":"publisher","first-page":"2848","DOI":"10.1172\/JCI99424","volume":"128","author":"C-P Liao","year":"2019","unstructured":"Liao C-P, Booker RC, Brosseau J-P, Chen Z, Mo J, Tchegnon E et al (2019) Contributions of inflammation and tumor microenvironment to neurofibroma tumorigenesis. J Clin Invest 128:2848\u20132861","journal-title":"J Clin Invest"},{"key":"2310_CR46","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.583084","volume":"11","author":"Y Pan","year":"2020","unstructured":"Pan Y, Yu Y, Wang X, Zhang T (2020) Tumor-associated macrophages in tumor immunity. Front Immunol 11:583084","journal-title":"Front Immunol"},{"key":"2310_CR47","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1038\/415536a","volume":"415","author":"L Monney","year":"2002","unstructured":"Monney L, Sabatos CA, Gaglia JL, Ryu A, Waldner H, Chernova T et al (2002) Th1-specific cell surface protein Tim-3 regulates macrophage activation and severity of an autoimmune disease. Nature 415:536\u2013541","journal-title":"Nature"},{"key":"2310_CR48","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1111\/imr.12520","volume":"276","author":"M Das","year":"2017","unstructured":"Das M, Zhu C, Kuchroo VK (2017) Tim-3 and its role in regulating anti-tumor immunity. Immunol Rev 276:97\u2013111","journal-title":"Immunol Rev"},{"key":"2310_CR49","doi-asserted-by":"publisher","first-page":"1650","DOI":"10.1038\/s41588-018-0251-4","volume":"50","author":"T Gayden","year":"2018","unstructured":"Gayden T, Sepulveda FE, Khuong-Quang D-A, Pratt J, Valera ET, Garrigue A et al (2018) Germline HAVCR2 mutations altering TIM-3 characterize subcutaneous panniculitis-like T cell lymphomas with hemophagocytic lymphohistiocytic syndrome. Nat Genet 50:1650\u20131657","journal-title":"Nat Genet"},{"key":"2310_CR50","doi-asserted-by":"publisher","first-page":"2366","DOI":"10.1016\/j.gendis.2022.05.020","volume":"10","author":"Y Lv","year":"2023","unstructured":"Lv Y, Ma X, Ma Y, Du Y, Feng J (2023) A new emerging target in cancer immunotherapy: Galectin-9 (LGALS9). Genes Dis 10:2366\u20132382","journal-title":"Genes Dis"},{"key":"2310_CR51","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.800928","volume":"12","author":"G Li","year":"2021","unstructured":"Li G, Huang R, Fan W, Wang D, Wu F, Zeng F et al (2021) Galectin-9\/TIM-3 as a key regulator of immune response in gliomas with chromosome 1p\/19q codeletion. Front Immunol 12:800928","journal-title":"Front Immunol"},{"key":"2310_CR52","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1495907","volume":"16","author":"C Knickmeier","year":"2025","unstructured":"Knickmeier C, Noubissi Nzeteu GA, Gibbs BF, Hoogwater FJH, Nijkamp MW, Bockhorn M et al (2025) It\u2019s about TIME: Gal-9 as a potential immunotherapeutic target in pancreatic ductal adenocarcinoma. Front Immunol 16:1495907","journal-title":"Front Immunol"},{"key":"2310_CR53","doi-asserted-by":"publisher","first-page":"9111","DOI":"10.3892\/mmr.2017.7719","volume":"16","author":"R Lv","year":"2017","unstructured":"Lv R, Bao Q, Li Y (2017) Regulation of M1\u2011type and M2\u2011type macrophage polarization in RAW264.7 cells by Galectin\u20119. Mol Med Rep 16:9111\u20139119","journal-title":"Mol Med Rep"},{"key":"2310_CR54","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1016\/j.yexcr.2019.02.007","volume":"376","author":"W Zhang","year":"2019","unstructured":"Zhang W, Zhang Y, He Y, Wang X, Fang Q (2019) Lipopolysaccharide mediates time-dependent macrophage M1\/M2 polarization through the Tim-3\/Galectin-9 signalling pathway. Exp Cell Res 376:124\u2013132","journal-title":"Exp Cell Res"},{"key":"2310_CR55","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1016\/j.stem.2015.07.011","volume":"17","author":"Y Kikushige","year":"2015","unstructured":"Kikushige Y, Miyamoto T, Yuda J, Jabbarzadeh-Tabrizi S, Shima T, Takayanagi S et al (2015) A TIM-3\/Gal-9 autocrine stimulatory loop drives self-renewal of human myeloid leukemia stem cells and leukemic progression. Cell Stem Cell 17:341\u2013352","journal-title":"Cell Stem Cell"},{"key":"2310_CR56","doi-asserted-by":"publisher","first-page":"1227","DOI":"10.1038\/ng.3095","volume":"46","author":"W Lee","year":"2014","unstructured":"Lee W, Teckie S, Wiesner T, Ran L, Prieto Granada CN, Lin M et al (2014) PRC2 is recurrently inactivated through EED or SUZ12 loss in malignant peripheral nerve sheath tumors. Nat Genet 46:1227\u20131232","journal-title":"Nat Genet"},{"key":"2310_CR57","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1097\/PAS.0000000000000564","volume":"40","author":"CN Prieto-Granada","year":"2016","unstructured":"Prieto-Granada CN, Wiesner T, Messina JL, Jungbluth AA, Chi P, Antonescu CR (2016) Loss of H3K27me3 expression is a highly sensitive marker for sporadic and radiation-induced MPNST. Am J Surg Pathol 40:479\u2013489","journal-title":"Am J Surg Pathol"},{"key":"2310_CR58","doi-asserted-by":"crossref","unstructured":"Yan J, Chen Y, Patel AJ, Warda S, Lee CJ, Nixon BG et al (2022) Tumor-intrinsic PRC2 inactivation drives a context-dependent immune-desert microenvironment and is sensitized by immunogenic therapeutic viruses. J Clin Invest e153437","DOI":"10.1172\/JCI153437"},{"key":"2310_CR59","doi-asserted-by":"publisher","first-page":"654","DOI":"10.1158\/2159-8290.CD-22-0786","volume":"13","author":"I Cortes-Ciriano","year":"2023","unstructured":"Cortes-Ciriano I, Steele CD, Piculell K, Al-Ibraheemi A, Eulo V, Bui MM et al (2023) Genomic patterns of malignant peripheral nerve sheath tumor (MPNST) evolution correlate with clinical outcome and are detectable in cell-free DNA. Cancer Discov 13:654\u2013671","journal-title":"Cancer Discov"},{"key":"2310_CR60","doi-asserted-by":"publisher","first-page":"3205","DOI":"10.1158\/0008-5472.CAN-18-3704","volume":"79","author":"JB Wojcik","year":"2019","unstructured":"Wojcik JB, Marchione DM, Sidoli S, Djedid A, Lisby A, Majewski J et al (2019) Epigenomic reordering induced by Polycomb loss drives oncogenesis but leads to therapeutic vulnerabilities in malignant peripheral nerve sheath tumors. Cancer Res 79:3205\u20133219","journal-title":"Cancer Res"},{"key":"2310_CR61","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-07452-y","volume":"9","author":"J-P Brosseau","year":"2018","unstructured":"Brosseau J-P, Liao C-P, Wang Y, Ramani V, Vandergriff T, Lee M et al (2018) NF1 heterozygosity fosters de novo tumorigenesis but impairs malignant transformation. Nat Commun 9:5014","journal-title":"Nat Commun"},{"key":"2310_CR62","doi-asserted-by":"publisher","first-page":"4486","DOI":"10.1158\/0008-5472.CAN-16-2643","volume":"77","author":"RD Dodd","year":"2017","unstructured":"Dodd RD, Lee C-L, Overton T, Huang W, Eward WC, Luo L et al (2017) NF1+\/- hematopoietic cells accelerate malignant peripheral nerve sheath tumor development without altering chemotherapy response. Cancer Res 77:4486\u20134497","journal-title":"Cancer Res"},{"key":"2310_CR63","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1038\/s41591-018-0263-8","volume":"25","author":"F D\u2019Angelo","year":"2019","unstructured":"D\u2019Angelo F, Ceccarelli M, Tala, Garofano L, Zhang J, Frattini V et al (2019) The molecular landscape of glioma in patients with Neurofibromatosis 1. Nat Med 25:176\u2013187","journal-title":"Nat Med"}],"container-title":["Acta Neuropathologica Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40478-026-02310-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40478-026-02310-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40478-026-02310-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T02:02:13Z","timestamp":1782180133000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s40478-026-02310-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,3]]},"references-count":63,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["2310"],"URL":"https:\/\/doi.org\/10.1186\/s40478-026-02310-1","relation":{},"ISSN":["2051-5960"],"issn-type":[{"value":"2051-5960","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,3]]},"assertion":[{"value":"23 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by an institutional review board (Comit\u00e9 de protection des personnes\u2014CPP Ile de France [CPP 20150-11-03]). All participants provided written informed consent.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All authors have approved the submission of this manuscript.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"133"}}